European Neuropsychopharmacology最新文献

英文中文

The role of esketamine in persistent long COVID with predominant psychiatric manifestations

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-02-27 DOI: 10.1016/j.euroneuro.2024.12.014

Ina Bozic , Dominik Ivkic , Lutz Reinfried , Jakob Donath , Clemens Schmidt , Samantha Graf , Patricia Handschuh , Markus Dold , Dietmar Winkler , Angela Naderi-Haiden , Nicole Praschak-Rieder , Dan Rujescu , Ana Weidenauer , Lucie Bartova

引用次数: 0

Measuring the clinical dimensions of negative symptoms through the Positive and Negative Syndrome Scale

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-02-27 DOI: 10.1016/j.euroneuro.2024.12.016

Noham Wolpe , Andrea Perrottelli , Luigi Giuliani , Zixu Yang , Gurpreet Rekhi , Peter B. Jones , Miquel Bernardo , Maria Paz Garcia-Portilla , Stefan Kaiser , Gabriel Robert , Phillipe Robert , Anna Mane , Silvana Galderisi , Jimmy Lee , Armida Mucci , Emilio Fernandez-Egea

The negative symptoms of schizophrenia can determine functional outcome in patients. Despite its clinical significance, no treatment exists to date, as numerous pharmacological and non-pharmacological clinical trials have failed to demonstrate efficacy. Many of these trials evaluated negative symptoms as a single clinical construct. However, consistent evidence in the past two decades has found that negative symptoms constitute at least two independent clinical dimensions, namely deficits in motivation and pleasure (MAP) and in emotional expression (EXP). These dimensions are best evaluated using new assessment tools, such as the Brief Negative Symptom Scale (BNSS). However, older assessment tools, and particularly the Positive and Negative Syndrome Scale (PANSS), remain widely used in past and current research. Here, we sought to predict BNSS MAP and EXP dimensions from the PANSS. Using complementary modelling approaches across three heterogeneous, multi-centre, multi-culture patient samples (n = 1241 patients, 1846 observations), we show that MAP can be estimated (43–60 % variance explained) predominantly using N2 and N4. Moreover, EXP can be estimated predominantly using the two PANSS items N1 and N6 (55–81 % variance explained across models and samples). Additionally, PANSS-derived MAP shows associations with functioning similar to those measured by the BNSS MAP dimension. Together, our results suggest that while EXP can be reliably estimated from PANSS, MAP cannot be consistently estimated from PANSS across samples and cultures. This warrants caution when using the PANSS to estimate MAP and emphasises the need for using the newer assessment tools for negative symptoms.

{"title":"Measuring the clinical dimensions of negative symptoms through the Positive and Negative Syndrome Scale","authors":"Noham Wolpe , Andrea Perrottelli , Luigi Giuliani , Zixu Yang , Gurpreet Rekhi , Peter B. Jones , Miquel Bernardo , Maria Paz Garcia-Portilla , Stefan Kaiser , Gabriel Robert , Phillipe Robert , Anna Mane , Silvana Galderisi , Jimmy Lee , Armida Mucci , Emilio Fernandez-Egea","doi":"10.1016/j.euroneuro.2024.12.016","DOIUrl":"10.1016/j.euroneuro.2024.12.016","url":null,"abstract":"<div><div>The negative symptoms of schizophrenia can determine functional outcome in patients. Despite its clinical significance, no treatment exists to date, as numerous pharmacological and non-pharmacological clinical trials have failed to demonstrate efficacy. Many of these trials evaluated negative symptoms as a single clinical construct. However, consistent evidence in the past two decades has found that negative symptoms constitute at least two independent clinical dimensions, namely deficits in motivation and pleasure (MAP) and in emotional expression (EXP). These dimensions are best evaluated using new assessment tools, such as the Brief Negative Symptom Scale (BNSS). However, older assessment tools, and particularly the Positive and Negative Syndrome Scale (PANSS), remain widely used in past and current research. Here, we sought to predict BNSS MAP and EXP dimensions from the PANSS. Using complementary modelling approaches across three heterogeneous, multi-centre, multi-culture patient samples (<em>n</em> = 1241 patients, 1846 observations), we show that MAP can be estimated (43–60 % variance explained) predominantly using N2 and N4. Moreover, EXP can be estimated predominantly using the two PANSS items N1 and N6 (55–81 % variance explained across models and samples). Additionally, PANSS-derived MAP shows associations with functioning similar to those measured by the BNSS MAP dimension. Together, our results suggest that while EXP can be reliably estimated from PANSS, MAP cannot be consistently estimated from PANSS across samples and cultures. This warrants caution when using the PANSS to estimate MAP and emphasises the need for using the newer assessment tools for negative symptoms.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 68-76"},"PeriodicalIF":6.1,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143508558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lack of transparency on baseline pharmacological treatments in Clinical High-Risk for psychosis (CHR-P) may degrade precision: A systematic review and meta-analysis

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-02-21 DOI: 10.1016/j.euroneuro.2025.01.007

Andrea Raballo , Michele Poletti , Antonio Preti

The field of Clinical High-Risk for Psychosis (CHR-P) is a dynamic area within contemporary psychiatry and serves as a crucial testing ground for precision prognostic models. Nonetheless, some foundational aspects remain inadequately conceptualized and consequently not transparently reported, such as baseline pharmacotherapy. A systematic review and meta-analysis were conducted by searching the MEDLINE and Cochrane Library databases for studies published up to August 31, 2024. Eligible studies included CHR-P samples, reported numeric data on outcomes at follow-up, and examined the transition to psychosis as an outcome. Data extraction adhered to PRISMA guidelines, focusing on baseline pharmacological exposure to antipsychotics, antidepressants, benzodiazepines, and mood stabilizers. A total of 95 studies were analyzed. The majority of studies (96.8 %) explicitly stated whether baseline exposure to antipsychotics was allowed as part of the inclusion criteria. However, actual baseline exposure to antipsychotics was quantified in only 60 % of these studies. Exposure to non-antipsychotic psychoactive therapies was reported in only a fraction of the studies (36.8 % for antidepressants, 16.8 % for benzodiazepines, and 14.7 % for mood stabilizers). In CHR-P longitudinal studies, the meta-analytic proportions of self-disclosed baseline pharmacological exposure ranged from 23.5 % to 24.5 % for antipsychotics, 28.5 % to 30.6 % for antidepressants, 11.2 % to 14.6 % for benzodiazepines, and 5.6 % to 5.9 % for mood stabilizers.

Overall, a non negligible fraction of CHR-P participants is already under psychoactive pharmacological treatment at enrollment. The lack of consistent transparency in this respect may limit the effectiveness of prognostic models. Improved reporting practices are necessary to enhance precision in preventive psychiatry.

{"title":"Lack of transparency on baseline pharmacological treatments in Clinical High-Risk for psychosis (CHR-P) may degrade precision: A systematic review and meta-analysis","authors":"Andrea Raballo , Michele Poletti , Antonio Preti","doi":"10.1016/j.euroneuro.2025.01.007","DOIUrl":"10.1016/j.euroneuro.2025.01.007","url":null,"abstract":"<div><div>The field of Clinical High-Risk for Psychosis (CHR-P) is a dynamic area within contemporary psychiatry and serves as a crucial testing ground for precision prognostic models. Nonetheless, some foundational aspects remain inadequately conceptualized and consequently not transparently reported, such as baseline pharmacotherapy. A systematic review and meta-analysis were conducted by searching the MEDLINE and Cochrane Library databases for studies published up to August 31, 2024. Eligible studies included CHR-P samples, reported numeric data on outcomes at follow-up, and examined the transition to psychosis as an outcome. Data extraction adhered to PRISMA guidelines, focusing on baseline pharmacological exposure to antipsychotics, antidepressants, benzodiazepines, and mood stabilizers. A total of 95 studies were analyzed. The majority of studies (96.8 %) explicitly stated whether baseline exposure to antipsychotics was allowed as part of the inclusion criteria. However, actual baseline exposure to antipsychotics was quantified in only 60 % of these studies. Exposure to non-antipsychotic psychoactive therapies was reported in only a fraction of the studies (36.8 % for antidepressants, 16.8 % for benzodiazepines, and 14.7 % for mood stabilizers). In CHR-P longitudinal studies, the meta-analytic proportions of self-disclosed baseline pharmacological exposure ranged from 23.5 % to 24.5 % for antipsychotics, 28.5 % to 30.6 % for antidepressants, 11.2 % to 14.6 % for benzodiazepines, and 5.6 % to 5.9 % for mood stabilizers.</div><div>Overall, a non negligible fraction of CHR-P participants is already under psychoactive pharmacological treatment at enrollment. The lack of consistent transparency in this respect may limit the effectiveness of prognostic models. Improved reporting practices are necessary to enhance precision in preventive psychiatry.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 58-65"},"PeriodicalIF":6.1,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143453098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The cumulative production and conjugation of steroid hormones during pregnancy predict postpartum depressive mood

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-02-21 DOI: 10.1016/j.euroneuro.2025.02.004

Anna Soler , Francisco Madrid-Gambín , Olha Khymenets , Camila Servin-Barthet , Magdalena Martínez-García , Maria Paternina-Die , Montserrat Montané-García , Clara Pretus , Susana Carmona , Óscar J. Pozo , Oscar Vilarroya

引用次数: 0

On the potential of xanomeline-trospium chloride for schizophrenia and beyond

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-02-16 DOI: 10.1016/j.euroneuro.2025.02.002

Nicholas Fabiano , Stanley Wong , Carl Zhou , Christoph U. Correll , Mikkel Højlund , Marco Solmi

引用次数: 0

Artificial intelligence in healthcare: Revolution or unfulfilled promise?

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-02-16 DOI: 10.1016/j.euroneuro.2025.01.006

Gerard Anmella , Enrique Baca-García

引用次数: 0

Prescription sequences in bipolar disorder – A nationwide Danish register-based study of 19,927 individuals followed for 10 years

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-02-16 DOI: 10.1016/j.euroneuro.2025.01.008

Anders Jorgensen , Mathilde Marie Brünnich Sloth , Emma Neble Larsen , Merete Osler , Lars Vedel Kessing

Evidence-based use of pharmacological interventions in bipolar disorder is of paramount clinical importance. We aimed to uncover precription sequences in a large cohort of patients from the first diagnosis of bipolar disorder. Using Danish nationwide registers, we identified individuals with a first-time hospital diagnosis of bipolar disorder between January 1^st, 2001, and December 31^st, 2016. Redemeed prescriptions of litihum, anticonvulsants, antipsychotics, and antidepressants from five years before to five years after diagnosis were retreived. The data were analysed with descriptive statistics, sunburst plots, and Cox proportioal hazard models. The full study population consisted of 19,927 individuals. Before diagnosis, antidepressants were the predominantly prescribed group (46.9 % as first drug). After diagnosis, a major trend towards mood stabilising strategies was observed. although only 18.7 % received lithiumas first prescription. In analyses stratified for illness phase, lithium was more frequently prescribed as first drug after depression than after hypomania/mania, in which antidepressants were used as first drug in 10-15 % of the cases. Treatment sequences were highly heterogeneous (2,459 distinct sequences for the 19,927 individuals under investigation). Lithium appeared to carry the overall highest risk of treatment shift. We conclude that in accordance with national and international guidelines, a diagnosis of bipolar disorder leads to a relevant change of treatment strategy towards mood stabilising drugs. However, lithium continues to be underused;antidepressants probably used too frequently, and treatment sequences are highly heterogeneous and not adjusted according to illness phase. These results point to a potential for optimising the real-world pharmacological management of bipolar disorder.

{"title":"Prescription sequences in bipolar disorder – A nationwide Danish register-based study of 19,927 individuals followed for 10 years","authors":"Anders Jorgensen , Mathilde Marie Brünnich Sloth , Emma Neble Larsen , Merete Osler , Lars Vedel Kessing","doi":"10.1016/j.euroneuro.2025.01.008","DOIUrl":"10.1016/j.euroneuro.2025.01.008","url":null,"abstract":"<div><div>Evidence-based use of pharmacological interventions in bipolar disorder is of paramount clinical importance. We aimed to uncover precription sequences in a large cohort of patients from the first diagnosis of bipolar disorder. Using Danish nationwide registers, we identified individuals with a first-time hospital diagnosis of bipolar disorder between January 1<sup>st</sup>, 2001, and December 31<sup>st</sup>, 2016. Redemeed prescriptions of litihum, anticonvulsants, antipsychotics, and antidepressants from five years before to five years after diagnosis were retreived. The data were analysed with descriptive statistics, sunburst plots, and Cox proportioal hazard models. The full study population consisted of 19,927 individuals. Before diagnosis, antidepressants were the predominantly prescribed group (46.9 % as first drug). After diagnosis, a major trend towards mood stabilising strategies was observed. although only 18.7 % received lithiumas first prescription. In analyses stratified for illness phase, lithium was more frequently prescribed as first drug after depression than after hypomania/mania, in which antidepressants were used as first drug in 10-15 % of the cases. Treatment sequences were highly heterogeneous (2,459 distinct sequences for the 19,927 individuals under investigation). Lithium appeared to carry the overall highest risk of treatment shift. We conclude that in accordance with national and international guidelines, a diagnosis of bipolar disorder leads to a relevant change of treatment strategy towards mood stabilising drugs. However, lithium continues to be underused;antidepressants probably used too frequently, and treatment sequences are highly heterogeneous and not adjusted according to illness phase. These results point to a potential for optimising the real-world pharmacological management of bipolar disorder.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 51-57"},"PeriodicalIF":6.1,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143420161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter to the editor concerning: “Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: A systematic review and meta-analysis”

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-02-16 DOI: 10.1016/j.euroneuro.2025.01.010

Chuntong Zhou , Junjing Miao , Haiyang Chen , Liuqing Shi , Mei Lu , Mingjie Li , Huan Han , Xin Zhou , Lu Ren

引用次数: 0

Methylation profile scores of environmental exposures and risk of relapse after a first episode of schizophrenia

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-02-16 DOI: 10.1016/j.euroneuro.2025.02.003

Alex-González Segura , Llucia Prohens , Laura Julià , Silvia Amoretti , Maria RIbero , Laura Pino-Camacho , Guillermo Cano-Escalera , Anna Mane , Roberto Rodriguez-Jimenez , Alexandra Roldan , Salvador Sarró , Angela Ibañez , Judith Usall , Antonio Lobo , Clemente Garcia-Rizo , Manuel Jesus Cuesta , Mara Parellada , Ana González-Pinto , Esther Berrocoso , Miquel Bernardo , Concepción De-la-Cámara

Both genetic and environmental factors have been found to play a significant role in psychosis relapse, either independently or through their synergistic interaction. Recently, DNA methylation (DNAm) has been proposed through the calculation of methylation profile scores (MPS). The aim of the present study is to evaluate the association of MPS as a surrogate marker of the biological impact of early stressful life events (including stressful intrauterine conditions and obstetric complications, childhood adversity and toxic habits), with the risk of schizophrenia (SCZ) relapse. 91 participants from a cohort of first-episode schizophrenia (FES) patients with less than five years of evolution were classified as non-relapse (patients who had not experienced a relapse after 3 years of enrollment) or relapse (patients who relapsed during the 3-year follow-up). As inclusion criteria, patients fulfilled Andreasen's criteria of symptomatic remission. Genome-wide DNA methylation (DNAm) was profiled and fourteen MPS reflecting environmental exposure were constructed including both early stressful life events (including stressful intrauterine conditions and delivery issues, childhood adversity) and toxic habits. Increased levels of MPS reflecting gestational diabetes (p = 0.009), hypertensive disorders during pregnancy (p = 0.004), pre-eclampsia (p = 0.049), early preterm birth (p = 0.030), childhood adversity abuse (p = 0.021) and all childhood adversity (p = 0.030) were significantly associated with an increased risk of relapse. Our study suggests that changes in specific methylation patterns may represent one of the biological mechanisms linking early stressful life events to an increased risk of relapse.

{"title":"Methylation profile scores of environmental exposures and risk of relapse after a first episode of schizophrenia","authors":"Alex-González Segura , Llucia Prohens , Laura Julià , Silvia Amoretti , Maria RIbero , Laura Pino-Camacho , Guillermo Cano-Escalera , Anna Mane , Roberto Rodriguez-Jimenez , Alexandra Roldan , Salvador Sarró , Angela Ibañez , Judith Usall , Antonio Lobo , Clemente Garcia-Rizo , Manuel Jesus Cuesta , Mara Parellada , Ana González-Pinto , Esther Berrocoso , Miquel Bernardo , Concepción De-la-Cámara","doi":"10.1016/j.euroneuro.2025.02.003","DOIUrl":"10.1016/j.euroneuro.2025.02.003","url":null,"abstract":"<div><div>Both genetic and environmental factors have been found to play a significant role in psychosis relapse, either independently or through their synergistic interaction. Recently, DNA methylation (DNAm) has been proposed through the calculation of methylation profile scores (MPS). The aim of the present study is to evaluate the association of MPS as a surrogate marker of the biological impact of early stressful life events (including stressful intrauterine conditions and obstetric complications, childhood adversity and toxic habits), with the risk of schizophrenia (SCZ) relapse. 91 participants from a cohort of first-episode schizophrenia (FES) patients with less than five years of evolution were classified as non-relapse (patients who had not experienced a relapse after 3 years of enrollment) or relapse (patients who relapsed during the 3-year follow-up). As inclusion criteria, patients fulfilled Andreasen's criteria of symptomatic remission. Genome-wide DNA methylation (DNAm) was profiled and fourteen MPS reflecting environmental exposure were constructed including both early stressful life events (including stressful intrauterine conditions and delivery issues, childhood adversity) and toxic habits. Increased levels of MPS reflecting gestational diabetes (<em>p</em> = 0.009), hypertensive disorders during pregnancy (<em>p</em> = 0.004), pre-eclampsia (<em>p</em> = 0.049), early preterm birth (<em>p</em> = 0.030), childhood adversity abuse (<em>p</em> = 0.021) and all childhood adversity (<em>p</em> = 0.030) were significantly associated with an increased risk of relapse. Our study suggests that changes in specific methylation patterns may represent one of the biological mechanisms linking early stressful life events to an increased risk of relapse.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"94 ","pages":"Pages 4-15"},"PeriodicalIF":6.1,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143421067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Whole-brain functional neuroimaging correlates of cognitive flexibility impairments in people with mental disorders: A transdiagnostic coordinate-based meta-analysis

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-02-16 DOI: 10.1016/j.euroneuro.2025.01.009

Nicola Meda , Margherita Baggio , Enrico Collantoni , Fabio Sambataro

Introduction

Set-shifting skills allow individuals to flexibly adapt their behavior against environmental feedback. Impairments of this cognitive control process represent the core features of heterogeneous mental disorders. However, it is unclear whether the neural mechanisms of set-shifting impairments are shared across different mental disorders.

Materials and methods

We systematically screened the neuroimaging literature and conducted a coordinate-based meta-analysis. Of 1930 publications, 22 functional neuroimaging studies investigating neural response differences during the performance of set-shifting paradigm on the scanner in individuals with a mental disorder, including schizophrenia, depression, anxiety disorder, neurodevelopmental disorders, eating disorders, obsessive-compulsive disorder, behavioral addiction were selected.

Results

We found significant hyperactivation responses during set-shifting in the right medial frontal/anterior cingulate gyrus, the right superior parietal lobule, and the left superior temporal gyrus in patients with schizophrenia, autism spectrum disorders, or generalized anxiety disorder.

Conclusions

Our findings suggest a common substrate of increased activity in the frontoparietal network (FPN) across mental disorders during set-shifting. FPN activation responses may represent a biomarker of altered cognition across traditional nosographic categories.

{"title":"Whole-brain functional neuroimaging correlates of cognitive flexibility impairments in people with mental disorders: A transdiagnostic coordinate-based meta-analysis","authors":"Nicola Meda , Margherita Baggio , Enrico Collantoni , Fabio Sambataro","doi":"10.1016/j.euroneuro.2025.01.009","DOIUrl":"10.1016/j.euroneuro.2025.01.009","url":null,"abstract":"<div><h3>Introduction</h3><div>Set-shifting skills allow individuals to flexibly adapt their behavior against environmental feedback. Impairments of this cognitive control process represent the core features of heterogeneous mental disorders. However, it is unclear whether the neural mechanisms of set-shifting impairments are shared across different mental disorders.</div></div><div><h3>Materials and methods</h3><div>We systematically screened the neuroimaging literature and conducted a coordinate-based meta-analysis. Of 1930 publications, 22 functional neuroimaging studies investigating neural response differences during the performance of set-shifting paradigm on the scanner in individuals with a mental disorder, including schizophrenia, depression, anxiety disorder, neurodevelopmental disorders, eating disorders, obsessive-compulsive disorder, behavioral addiction were selected.</div></div><div><h3>Results</h3><div>We found significant hyperactivation responses during set-shifting in the right medial frontal/anterior cingulate gyrus, the right superior parietal lobule, and the left superior temporal gyrus in patients with schizophrenia, autism spectrum disorders, or generalized anxiety disorder.</div></div><div><h3>Conclusions</h3><div>Our findings suggest a common substrate of increased activity in the frontoparietal network (FPN) across mental disorders during set-shifting. FPN activation responses may represent a biomarker of altered cognition across traditional nosographic categories.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 40-50"},"PeriodicalIF":6.1,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143420160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

European Neuropsychopharmacology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀